ClinicalTrials.Veeva
Menu

Find clinical trials for Ovarian Cancer in Paris, Île-de-France

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Endometrial Cancer
Breast Cancer
Ovarian Epithelial Carcinoma
Cancer
Fallopian Tube Cancer
Non-Small-Cell Lung Carcinoma
Triple Negative Breast Cancer

Ovarian Cancer trials near Paris, Île-de-France, FRA:

Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

This Open-Label Extension (OLE) study provides participants with recurrent low-grade serous ovarian cancer (LGSOC) who have complet...

Not yet enrolling
Low Grade Ovarian Serous Adenocarcinoma
Ovarian Cancer
Drug: avutometinib + defactininb combination

Phase 2

Verastem

Paris, France and 1 other location

in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry \[IHC\] 3+/2+/1+) advanced high-grade epithelial ovarian...

Enrolling
Ovarian Cancer
Drug: Trastuzumab Deruxtecan
Drug: Bevacizumab

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Paris, France and 207 other locations

The goal of this clinical trial is to learn if the experimental antibody COM701 delays the progression of ovarian cancer in partici ...

Enrolling
Ovarian Cancer
Ovarian Cancer Recurrent
Drug: Normal Saline
Drug: COM701

Phase 1, Phase 2

Compugen

Villejuif, France and 27 other locations

of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...

Active, not recruiting
Relapsed Ovarian Cancer
Following Complete or Partial Response to Platinum Based Chemotherapy
Drug: Placebo to match olaparib 300mg
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Paris, France and 126 other locations

followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian ...

Active, not recruiting
Advanced Ovarian Cancer
Drug: Bevacizumab
Drug: Durvalumab placebo

Phase 3

AstraZeneca
AstraZeneca

Paris, France and 213 other locations

the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian...

Active, not recruiting
Low Grade Ovarian Serous Adenocarcinoma
Ovarian Cancer
Drug: avutometinib (VS-6766) and defactinib
Drug: avutometinib (VS-6766)

Phase 2

Verastem

Paris, France and 46 other locations

Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpos ...

Enrolling
Ovarian Cancer
Drug: Bevacizumab
Drug: Mirvetuximab Soravtansine

Phase 2

AbbVie
AbbVie

Villejuif, Île-de-France Region, France and 81 other locations

choice of chemotherapy in subjects with platinum-resistant ovarian cancer whose tumors are positive for cyclin E1 protein ...

Enrolling
Ovarian Cancer
Drug: Azenosertib
Drug: Investigator's choice of Chemotherapy

Phase 3

K-Group Beta

Paris, France and 58 other locations

in combination with first-line chemotherapy in patients with ovarian cancer. The main questions it aims to answer are:* What is the...

Not yet enrolling
Ovarian Cancer
Drug: GCSF
Drug: Chemotherapy

Phase 1, Phase 2

ARCAGY/ GINECO GROUP

Villejuif, France and 10 other locations

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....

Active, not recruiting
Advanced Ovarian Cancer
FIGO Stage III-IV
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Paris, France and 176 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems